The human papillomavirus (HPV) capsid is mainly composed of the L1 protein that can self-assemble into virus-like particles (VLPs) that are structurally and immunologically similar to the infectious virions. We report here the characterization of RNA aptamers that recognize baculovirus-produced HPV-16 L1 VLPs. Interaction and slot-blot binding assays showed that all isolated aptamers efficiently bound HPV-16 VLPs, although the Sc5-c3 aptamer showed the highest specificity and affinity (Kd=0.05 pM). Sc5-c3 secondary structure consisted of a hairpin with a symmetric bubble and an unstructured 3′end. Biochemical and genetic analyses showed that the Sc5-c3 main loop is directly involved on VLPs binding. In particular, binding specificity appeared mediated by five non-consecutive nucleotide positions. Experiments using bacterial-produced HPV-16 L1 resulted in low Sc5-c3 binding, suggesting that recognition of HPV-16 L1 VLPs relies on quaternary structure features not present in bacteria-produced L1 protein. Sc5-c3 produced specific and stable binding to HPV-16 L1 VLPs even in biofluid protein mixes and thus it may provide a potential diagnostic tool for active HPV infection.
Get full access to this article
View all access options for this article.
References
1.
HermannT and PatelDJ. (2000). Adaptive recognition by nucleic acid aptamers. Science, 287:820–825.
2.
TuerkC and GoldL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249:505–510.
3.
EllingtonAD and SzostakJW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
4.
JayasenaSD. (1999). Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem, 45:1628–1650.
5.
SundaramP, KurniawanH, ByrneME and WowerJ. (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci, 48:25–9271.
6.
ZhuG, YeM, DonovanMJ, SongE, ZhaoZ and TanW. (2012). Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb), 48:10472–10480.
7.
SchiffmanM and WentzensenN. (2013). Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev, 22:553–560.
8.
Zur HausenH. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2:342–350.
9.
BishopB, DasguptaJ and ChenXS. (2007). Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly. Virol J, 4:3–8.
10.
FinnenRL, EricksonKD, ChenXS and GarceaRL. (2003). Interactions between papillomavirus L1 and L2 capsid proteins. J Virol, 77:4818–4826.
11.
de VilliersEM, FauquetC, BrokerTR, BernardHU and zurHH. (2004). Classification of papillomaviruses. Virology, 324:17–27.
12.
KirnbauerR, BooyF, ChengN, LowyDR and SchillerJT. (1992). Papillomavirus L1 major capsid protein self-assembles into virus- like particles that are highly immunogenic. Proc Natl Acad Sci U S A, 89:12180–12184.
13.
FliggeC, SchaferF, SelinkaHC, SappC and SappM. (2001). DNA-induced structural changes in the papillomavirus capsid. J Virol, 75:7727–7731.
14.
DasguptaJ, Bienkowska-HabaM, OrtegaME, PatelHD, BodevinS, SpillmannD, BishopB, SappM and ChenXS. (2011). Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem, 286:2617–2624.
15.
VarsaniA, WilliamsonAL, deVD, BeckerI, ChristensenND and RybickiEP. (2003). Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol, 77:8386–8393.
16.
XuYF, ZhangYQ, XuXM and SongGX. (2006). Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol, 151:2133–2148.
17.
WindramOP, WeberB, JafferMA, RybickiEP, ShepherdDN and VarsaniA. (2008). An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins. Arch Virol, 153:585–589.
18.
BousarghinL, TouzeA, GaudG, IochmannS, AlvarezE, ReverdiauP, GaitanJ, JourdanML, SizaretPY and CoursagetPL. (2009). Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther, 8:357–365.
19.
KeamSJ and HarperDM. (2008). Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs, 68: 359–372.
20.
Alvarez-SalasLM. (2008). Nucleic acids as therapeutic agents. Curr Top Med Chem, 8:1379–1404.
21.
MeyerM, ScheperT and WalterJG. (2013). Aptamers: versatile probes for flow cytometry. Appl Microbiol Biotechnol, 97:7097–7109.
22.
ZhouJ, TiemannK, ChomchanP, AlluinJ, SwiderskiP, BurnettJ, ZhangX, FormanS, ChenR and RossiJ. (2013). Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res, 41:4266–4283.
23.
Toscano-GaribayJD, Benitez-HessML and Alvarez-SalasLM. (2011). Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch Med Res, 42:88–96.
24.
NicolC, BunkaDH, BlairGE and StonehouseNJ. (2011). Effects of single nucleotide changes on the binding and activity of RNA aptamers to human papillomavirus 16 E7 oncoprotein. Biochem Biophys Res Commun, 405:417–421.
25.
NicolC, CesurO, ForrestS, BelyaevaTA, BunkaDH, BlairGE and StonehouseNJ. (2013). An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein. PLoS ONE, 8:e64781–e64791.
26.
GrahamJC and ZarblH. (2012). Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS ONE, 7:e36103–e36111.
27.
KirnbauerR, TaubJ, GreenstoneH, RodenR, DurstM, GissmannL, LowyDR and SchillerJT. (1993). Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 67:6929–6936.
28.
Benitez-HessML, DiPaoloJA and Alvarez-SalasLM. (2004). Antisense activity detection by inhibition of fluorescence resonance energy transfer. Luminescence, 19:85–93.
29.
Toscano-GaribayJD, Benitez-HessML and Alvarez-SalasLM. Targeting of the HPV-16 E7 Protein by RNA Aptamers. In: Cervical Cancer, vol. 2. KepplerD and LinAW, eds. (2014). Humana Press Inc., New York, NY.
30.
WongI and LohmanTM. (1993). A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci U S A, 90:5428–5432.
31.
GoodrichJA and KugelJF, eds. Binding and kinetics for molecular biologists. (2007). CSH Laboratory Press, Cold Spring Harbor, NY.
32.
DahlquistFW. (1978). The meaning of Scatchard and Hill plots. Methods Enzymol, 48:270–299.
33.
BousarghinL, TouzeA, Combita-RojasAL and CoursagetP. (2003). Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol, 84:157–164.
34.
ZukerM. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 31:3406–3415.
35.
ZhengZZ, SunYY, ZhaoM, HuangH, ZhangJ, XiaNS, MiaoJ and ZhaoQ. (2013). Specific interaction between hnRNP H and HPV16 L1 proteins: implications for late gene auto-regulation enabling rapid viral capsid protein production. Biochem Biophys Res Commun, 430:1047–1053.
36.
WangJ, JiangH and LiuF. (2000). In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA, 6:571–583.
37.
GopinathSC and KumarPK. (2013). Aptamers that bind to the hemagglutinin of the recent pandemic influenza virus H1N1 and efficiently inhibit agglutination. Acta Biomater, 9:8932–8941.
38.
KangJ, LeeMS, WatowichSJ and GorensteinDG. (2007). Combinatorial selection of a RNA thioaptamer that binds to Venezuelan equine encephalitis virus capsid protein. FEBS Lett, 581:2497–2502.
39.
GopinathSC, SakamakiY, KawasakiK and KumarPK. (2006). An efficient RNA aptamer against human influenza B virus hemagglutinin. J Biochem (Tokyo), 139:837–846.
40.
YoonS, LeeG, HanD, SongJY, KangKS and LeeYS. (2010). Neutralization of infectivity of porcine circovirus type 2 (PCV2) by capsid-binding 2′F-RNA aptamers. Antiviral Res, 88:19–24.
41.
VolpersC, SappM, SnijdersPJ, WalboomersJM and StreeckRE. (1995). Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. J Gen Virol, 76:2661–2667.
42.
ChoiSK, LeeC, LeeKS, ChoeSY, MoIP, SeongRH, HongS and JeonSH. (2011). DNA aptamers against the receptor binding region of hemagglutinin prevent avian influenza viral infection. Mol Cells, 32:527–533.
43.
ParkSY, KimS, YoonH, KimKB, KalmeSS, OhS, SongCS and KimDE. (2011). Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther, 21:395–402.
44.
YangD, MengX, YuQ, XuL, LongY, LiuB, FangX and ZhuH. (2013). Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother, 57:4937–4944.
FangNX, FrazerIH, ZhouJ and FernandoGJ. (1999). Post translational modifications of recombinant human papillomavirus type 6b major capsid protein. Virus Res, 60:113–121.
47.
FangNX, FrazerIH and FernandoGJ. (2000). Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnol Appl Biochem, 32:27–33.
48.
DeschuyteneerM, ElouahabiA, PlainchampD, PlisnierM, SoeteD, CorazzaY, LockmanL, GianniniS and DeschampsM. (2010). Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin, 6:407–419.
49.
ModisY, TrusBL and HarrisonSC. (2002). Atomic model of the papillomavirus capsid. EMBO J, 21:4754–4762.
50.
ChenXS, GarceaRL, GoldbergI, CasiniG and HarrisonSC. (2000). Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell, 5:557–567.
51.
KnappeM, BodevinS, SelinkaHC, SpillmannD, StreeckRE, ChenXS, LindahlU and SappM. (2007). Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem, 282:27913–27922.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
